

Industry Sessions

The program is preliminary and is a subject to change.

The below sessions are not included in main event CME/CPD credits.

13:30 – 14:00 PRE-CONFERENCE INDUSTRY SESSION

Plenary Hall (Hall Ramblas A+B)

Boehringer Ingelheim: Early Action, Lasting Impact – Primary Care Providers Hold the Key

Per-Henrik Groop, University of Helsinki, Finland

Baruch Itzhak, Clalit Health Services, Israel

16:25 – 17:55 INDUSTRY SYMPOSIUM BY AstraZeneca

Plenary Hall (Hall Ramblas A+B)

Chair: Baruch Itzhak, Clalit Health Services, Israel

16:25 – 16:55

Dapagliflozin as a disease modifying drug in Chronic Kidney Disease

Ana Cebrián, Murcian Health Service, Spain

16:55 – 17:10

Dapagliflozin as a disease modifying drug in Cardiovascular Disease

Mikhail Kosiborod, Saint Luke's Health System, USA

17:10 – 17:25

Sustainability and Chronic Kidney Disease

Kumaran Krishnan, AstraZeneca, Switzerland

17:25 – 17:40

**Making the Change for Kidney Health through policy change
AstraZeneca video**

17:40 – 17:55

Q&A and Discussion

12:20 – 13:30 INDUSTRY SESSION

Plenary Hall (Hall Ramblas A+B)

12:20 – 12:40 AstraZeneca: Our vision and pipeline in Cardiovascular, Renal & Metabolism

Elmas Malvolti, AstraZeneca, UK

12:40 – 13:00 Bayer: Finerenone in Practice – Bridging evidence and guidelines with clinical use

Ana Cebrián, Murcian Health Service, Spain

13:00 – 13:30 Novo Nordisk Israel:

Early therapy in type 2 diabetes

Avraham Karasik, Tel Aviv University, Israel

More Than Weight: Current Perspectives of Primary Care

Dan Oieru, Maccabi Health Services, Israel